导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.65% | 3148/4773 |
| 近一周 | -2.00% | 1050/5462 |
| 近一月 | -2.13% | 1167/5421 |
| 近一季 | -2.22% | 1214/5209 |
| 近半年 | -1.55% | 1629/4920 |
| 近一年 | -0.68% | 2761/4366 |
| 近两年 | 37.00% | 2011/2954 |
| 近三年 | 23.14% | 1359/2253 |
| 成立以来 | 217.13% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.46% 4146/4961 |
7.51% 2694/5312 |
- - |
- - |
| 2025 | 16.48% 2452/4813 |
-0.29% 2187/3635 |
2.93% 1255/4076 |
11.11% 3199/4524 |
2.15% 1066/4813 |
| 2024 | 18.31% 612/3463 |
3.45% 569/2808 |
-0.16% 695/3014 |
16.86% 1329/3129 |
-1.98% 1916/3463 |
| 2023 | -9.17% 1118/2656 |
0.89% 1676/2280 |
-4.84% 1304/2385 |
1.69% 289/2515 |
-6.97% 1996/2655 |
| 2022 | -17.24% 566/2207 |
-11.44% 512/1919 |
6.50% 683/2016 |
-13.57% 921/2113 |
1.51% 1239/2208 |
| 2021 | -4.94% 966/1822 |
-1.17% 442/1255 |
1.63% 1040/1330 |
-7.81% 1084/1466 |
2.66% 544/1822 |
| 2020 | 26.58% 602/1250 |
-10.71% 802/1028 |
12.83% 665/1067 |
10.92% 495/1164 |
13.27% 374/1184 |
| 2019 | 34.98% 386/1092 |
21.89% 588/754 |
3.10% 62/804 |
-0.39% 593/850 |
7.83% 390/918 |
| 2018 | -17.38% 129/834 |
- - |
- - |
- - |
-13.45% 534/691 |
| 2017 | 29.69% 63/714 |
- - |
- - |
- - |
- - |
| 2016 | 5.08% 36/605 |
- - |
- - |
- - |
- - |
| 2015 | 24.78% 93/575 |
- - |
- - |
- - |
- - |
| 2014 | 42.86% 117/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 万家上证50ETF VS. 长安沪深300非周期A(740101) |